Lanean...

New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma

Diffuse large B cell lymphoma (DLBCL) accounts for nearly 40% of non-Hodgkin’s lymphoma cases. The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refra...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Transl Res
Egile Nagusiak: Yu, Xin, Li, Zheng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: e-Century Publishing Corporation 2015
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731655/
https://ncbi.nlm.nih.gov/pubmed/26885255
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!